Avinger (NASDAQ:AVGR) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Avinger (NASDAQ:AVGR) in a research report sent to investors on Thursday. The firm issued a hold rating on the medical device company’s stock.

Separately, HC Wainwright restated a buy rating and issued a $5.00 price target on shares of Avinger in a report on Thursday, March 21st.

Avinger Trading Down 2.1 %

Shares of NASDAQ AVGR opened at $1.86 on Thursday. The firm has a 50 day moving average of $2.79 and a 200 day moving average of $3.00. The firm has a market capitalization of $3.17 million, a price-to-earnings ratio of -0.10 and a beta of 1.12. Avinger has a 12-month low of $1.59 and a 12-month high of $18.00.

Avinger (NASDAQ:AVGR) last released its earnings results on Wednesday, May 15th. The medical device company reported ($2.49) EPS for the quarter, missing the consensus estimate of ($1.35) by ($1.14). The firm had revenue of $1.86 million for the quarter, compared to analysts’ expectations of $2.36 million. Sell-side analysts predict that Avinger will post -2.08 EPS for the current year.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.